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https://doi.org/10.1186/s13046-019-1036-zRESEARCH Open AccessMelatonin synergizes BRAF-targeting agent
vemurafenib in melanoma treatment by
inhibiting iNOS/hTERT signaling and
cancer-stem cell traits
Jiaojiao Hao1†, Wenhua Fan2†, Yizhuo Li2†, Ranran Tang3†, Chunfang Tian1, Qian Yang1, Tianhua Zhu1,
Chaoliang Diao1, Sheng Hu1, Manyu Chen1, Ping Guo1, Qian Long2, Changlin Zhang2, Ge Qin2, Wendan Yu1,
Miao Chen2, Liren Li2, Lijun Qin4, Jingshu Wang4, Xiuping Zhang5, Yandong Ren5, Penghui Zhou2, Lijuan Zou1,
Kui Jiang1*, Wei Guo1* and Wuguo Deng2*Abstract
Background: As the selective inhibitor of BRAF kinase, vemurafenib exhibits effective antitumor activities in patients
with V600 BRAF mutant melanomas. However, acquired drug resistance invariably develops after its initial treatment.
Methods: Immunohistochemical staining was performed to detect the expression of iNOS and hTERT, p-p65, Epcam,
CD44, PCNA in mice with melanoma xenografts. The proliferation and migration of melanoma cells were detected by
MTT, tumorsphere culture, cell cycle, cell apoptosis, AO/EB assay and colony formation, transwell assay and scratch
assay in vitro, and tumor growth differences were observed in xenograft nude mice. Changes in the expression of key
molecules in the iNOS/hTERT signaling pathways were detected by western blot. Nucleus-cytoplasm separation, and
immunofluorescence analyses were conducted to explore the location of p50/p65 in melanoma cell lines. Flow
cytometry assay were performed to determine the expression of CD44. Pull down assay and ChIP assay were
performed to detect the binding ability of p65 at iNOS and hTERT promoters. Additionally, hTERT promoter-driven
luciferase plasmids were transfected in to melanoma cells with indicated treatment to determine luciferase activity of
hTERT.
Results: Melatonin significantly and synergistically enhanced vemurafenib-mediated inhibitions of proliferation, colony
formation, migration and invasion and promoted vemurafenib-induced apoptosis, cell cycle arresting and stemness
weakening in melanoma cells. Further mechanism study revealed that melatonin enhanced the antitumor effect of
vemurafenib by abrogating nucleus translocation of NF-κB p50/p65 and their binding at iNOS and hTERT promoters,
thereby suppressing the expression of iNOS and hTERT. The elevated anti-tumor capacity of vemurafenib upon co-
treatment with melatonin was also evaluated and confirmed in mice with melanoma xenografts.
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Conclusions: Collectively, our results demonstrate melatonin synergizes the antitumor effect of vemurafenib in human
melanoma by inhibiting cell proliferation and cancer-stem cell traits via targeting NF-κB/iNOS/hTERT signaling pathway,
and suggest the potential of melatonin in antagonizing the toxicity of vemurafenib and augmenting its sensitivities in
melanoma treatment.
Keywords: Melatonin, Vemurafenib, NF-κB, iNOS, hTERT, Cancer stem cellIntroduction
Melanoma is one of the most threatening malignancies and
has high metastatic potential. Although in the recent years,
significant progresses have been made in melanoma treat-
ment with the appearance and widespread application of
the combinational immunotherapy [1–4], it is still necessary
to explore other treatment options to get better clinical out-
put because the response rates to immunotherapy are not
100%. This might be mainly due to that the antigens
selected for these approaches do not cover the full
spectrum of melanoma cells present in a tumor [5, 6]. The
studies on cancer stem cells in melanoma raise the possibil-
ity that this long-lived tumor subpopulation is resistant to
clinical therapy [7]. Normal stem cells are thought to
achieve their longevity by several mechanisms among
which are slow divisions, anti-apoptotic mechanisms, and
expression of efflux pumps that provide protection from
toxins [7, 8], and the design of more effective therapeutic
strategies targeting melanoma stem cells and associated
molecular pathways and their application hold promise for
melanoma treatment. Inflammation is an important feature
of the tumor microenvironment in melanoma, and previous
studies showed that inducible nitric oxide synthase (INOS),
one of the most common inflammation factors, is an im-
portant inducer of melanoma tumorigenesis, tumor growth,
invasion and metastasis [9, 10], and INOS abrogation has
been proved to contribute to melanoma treatment.
BRAF mutations have been found in melanoma [11, 12],
and V600E is the most common mutation in BRAF leading
to constitutive activation of the MAPK signaling pathway
in malignant melanomas [13]. The MAPK signaling path-
way is involved in activation of BRAF which phosphorylates
and activates MEK, and in turn phosphorylates and acti-
vates ERK [14]. These reactions result in the activation of
transcription factors that regulate cell survival, proliferation
and differentiation. Vemurafenib, a small molecule inhibitor
of serine/threonine protein kinase BRAF, shows initial good
clinical responses [15]. Unfortunately, the relative initial
success of vemurafenib has been dampened by the develop-
ment of acquired resistance to the drug [16]. Moreover, the
patients received vemurafenib treatment easily present a se-
vere anterior uveitis secondary to this drug. In general, the
reactivation of MAPK signaling pathway, the bypass ofoncogenic pathway via activation of alternative signaling
pathways, and other uncharacterized mechanisms are con-
sidered to be the cause of therapeutic resistance in
kinase-driven cancers [17–19].
Melatonin (N-acetyl-5-methoxytryptamine) is a ubiqui-
tous physiological mediator secreted by the pineal gland.
In mammals, the pineal gland [20, 21] secretes melatonin
into the blood circulation to exert a range of well-
documented physiological functions [22]. It is well-known
melatonin is an important endogenous synchronizer of
the circadian day–night rhythm and seasonal biorhythms
on a variety of target organs [23–25]. Functionally, mela-
tonin has been widely documented because of its signifi-
cant antitumor effects on the ovarian carcinoma [26],
human melanoma [27] and breast cancer [28] et.al. In
addition, melatonin can induce cancer cell apoptosis and
suppress tumor metastasis, angiogenesis and inflamma-
tory reaction, which indicate its potential clinical applica-
tions [29–31]. Melatonin has been shown to function as a
potent combination therapeutic agent in human cancer
cells by enhancing the efficacy of conventional anticancer
agents and meanwhile reducing their side effects [32–34].
Notably, melatonin reduces cancer cell proliferation and
decreases self-renewal and clonogenic capability through
the decreased expression of stem cell markers [35]. How-
ever, the mechanisms associated with the melatonin-
regulated gene expression remain unclear. Therefore, it is
important to clarify the underlying molecular mechanisms
involved in the combination and to discover newly poten-
tial therapeutic targets.
In this study, we assessed the role of melatonin in the
enhancement of the vemurafenib-mediated antitumor
effect and identified the underlying mechanism of the
combination treatment in melanoma.
Methods
Cell lines and cell culture
Human melanoma cell lines SK-Mel-28, A375, A431 and
G361 were all obtained from the American Type Culture
Collection (ATCC). All the cells were grown in Dulbecco,s
Modified Eagle Medium (HyClone, Thermo Scientific)
supplemented with 10% heat-inactivated fetal bovine
serum (Gibco).
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vemurafenib resistances
Briefly, we cultivated A375 cells under the treatment of
increasing amounts of vemurafenib (VE), firstly 0.5 μM
VE was used for 2 weeks, and then 1μΜ VE was added
as a part of the culture medium. Cells that survive the
conditions were selected and amplified.
Western blot
Proteins from melanoma cell lysate were quantified
using a BCA protein assay kit and were loaded onto a
10% polyacrylamide gel (SDS-PAGE), then then trans-
ferred onto a polyvinylidene fluoride (PVDF, Millipore,
USA) membrane. Western blots were incubated with the
specific primary antibodies. Finally immunoreactivity
were detected by enhanced chemiluminescence.
Reagents and antibodies
Melatonin was purchased from J&K, Chemical Ltd.
Vemurafenib was obtained from Selleck (PLX4032) and
dissolved in dimethyl sulphoxide (DMSO) before
addition to the complete cell culture medium. For the
experiment, the solution of melatonin (1M) and vemur-
afenib (VE) (10 mM) in DMSO was prepared and kept
at 4 °C for further dilution in culture medium to main-
tain stability of used drugs. The InSolution™ NF-κB
Activation Inhibitor controlling the biological activity of
NF-κB (481407) was bought from Merck Millipore.
Antibodies against β-catenin, MMP-1, MMP-9, Apaf-1
were purchased from Santa Cruz (USA). The antibodies
against β-actin, IKKα, IKKβ, p-IKKα/β, IκB-α, p-IκB-α,
cleaved caspase-3, cleaved caspase-9, cleaved PARP,
Bcl-2, NF-κB p50, p65, p-PDK1, p-PTEN, p-AKT and
AKT were purchased from Cell Signaling Technology
(USA). The anti-TFIIB, E-cadherin antibodies were pur-
chased from Proteintech group (USA), and anti-iNOS
antibody was purchased from Wanlei Biotechnology
(China). The anti-BRAF V600E antibody was purchased
from Omnimabs (USA).
Plasmid vectors
The transfection was performed using Lipofectamine
3000 reagent (Invitrogen, Carlsbad, CA). Recombinant
plasmid vectors pGL3-hTERT-438 expressing luciferase
driven by hTERT promoter (− 378 to + 60) were produced
in our lab.
Tumorsphere culture
Cells with indicated treatment were digested into single
cell with trypsin-EDTA and were respectively seeded in
35mm non-treated cell culture dishes (BIOFIL, 2000
cells/dish) with continuous culture in DMEM/F12
medium (HyClone) containing B27 supplement (Gibco),
N2 supplement (Gibco), bFGF (20 ng/ml), and EGF (20ng/ml) for two weeks. Then the pictures of the formed
tumorspheres were taken by inverted microscope (Leica)
and the number of the spheres with diameter larger than
50um was counted.Flow cytometry assay of CD44
Expression of stemness-associated marker, CD44, was
detected by flow cytometer. A375 and SK-MEL-28 cells
with indicated treatment were digested with trypsin-
EDTA and washed twice in PBS containing 2% BSA and
centrifuged at 300×g for 3 min. Cells were divided into
two groups and resuspended in 100 ul PBS with 2% BSA
on ice. Then the antibody APC-IgG and APC-CD44 (BD
Pharmingen) were respectively added into single tube of
each group on ice to incubate for 30 min. The fluores-
cence value was detected finally by FACS Accuri C6
(Genetimes Technology Inc.).Cell viability assay
Cell viability was assessed using the MTT assay (Roche
Diagnosis, Indianapolis, IN). Briefly, melanoma cell lines
were seeded onto 96 well plates for following overnight
incubation. Five replicated wells were put up for each
group. Then cells were treated with melatonin or
vemurafenib by indicated dose. Finally, the effect for
cell viability was assessed by the absorbance of the
supernatant at a wavelength of 450 nm comparing to
the vehicle-treated control group. The drug concen-
tration required to cause 50% cell growth inhibition
(IC50) was determined by interpolation from dose-
response curves.Colony formation assay
Melanoma cells were seeded into six well plate (2 × 103
per well) and were incubated for 12 h. Then, the
medium was removed and cells were exposed to various
drugs. After 24 h, cells were changed into fresh medium
containing 10% FBS and incubated in a 37 °C, 5% CO2
incubator for 14 days until cells grew into macroscopic
colonies. Finally, the medium was removed, and the col-
onies were stained by 0.1% crystal violet and counted.Scratch assay
A375 and SK-mel-28 cells treated with indicated doses
of vemurafenib or melatonin. The cells were seeded into
six-well plates and incubated in the medium with 2.5%
FBS until grown to full confluency, then scraped by a
sterile 200 μl pipette tip. After 36 h, medium was re-
placed with PBS buffer and the wound gap was photo-
graphed by inverted microscope (Leica DM 14000B
microscope fixed with digital camera) at 0 h and 48.
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For the transwell assay, 4 × 104 cells were treated with
indicated doses of vemurafenib or melatonin per cham-
ber were plated. Cells were allowed to invade through
the matrigel-coated inserts. After the cells that remained
in the gel or attached to the upper side of the filter were
removed with cotton swabs, the invaded cells were
stained with 0.1% crystal violet solution and then was
photographed using a Leica DM 14000B microscope
fixed with digital camera. Finally, we used image-Pro
plus software for counting the invaded cells. The
concrete steps are as following: First, load the file to be
analyzed from the folder, and then select the rectangular
AOI tool, define the AOI to cover the image, and click
on select colors in the Count/Size dialog box, and select
Histogram Based button to set the range. Next, from the
Measure menu in the Count/Size dialog box, select the
Select Measurements command. Add the Area measure-
ment in the Filter Ranges, and set the threshold, then
click on Measure, and click the count in the Count/Size
dialog box. From the View menu in the Count/Size dia-
log box, select the Statistics command.
Cell cycle and apoptosis assay
In brief, A375 and SK-mel-28 cells (105 cells) seeded in
6-well plates were treated with indicated doses of
vemurafenib or melatonin. Cell cycle assay: after 48 h,
cells were collected and stained DNA with PI, finally
sorted by FACS Accuri C6 (Genetimes Technology Inc.)
and analyzed by using FlowJo 7.6 software; Apoptosis
assay: after 48 h, cells were collected subsequently
stained simultaneously with FITC-labeled annexin V and
PI. Stained cells were analyzed using FACS Accuri C6
(Genetimes Technology Inc.).
Acridine orange /ethidium bromide fluorescence staining
A375 or SK-mel-28 cells were grown on chamber slides
and treated with indicated doses of vemurafenib or
melatonin. After 48 h, cells were washed by PBS, and
then fixed by 95% ethanol for 15 min. After slightly
drying cells, 5 ul AO/EB (50 μg/ml) were added with
gently pipetting to mix before photographing by Leica
DM 14000B microscope fitted with digital camera.
Pulldown assay
The biotin-labeled double-stranded oligonucleotide
probes, which correspond to hTERT promoter sequence
or iNOS promoter sequence, were synthesized by PCR
using biotin-labeled primers from TAKARA Company.
The nucleus proteins (400 μg) were mixed with
double-strand biotinylated hTERT or iNOS promoter
probe (4 μg), streptavidin agarose beads (50 ml) in 500
ml PBSI buffer (0.5 mM PMSF, 10 mM NaF, 25 mM
β-glycerophosphate) and rotated for 4 h at RT. Thebeads were centrifuged, washed with PBSI buffer for two
times, and then were resuspended by loading buffer and
boiled at 100 °C for 10 min. The supernatant was
analyzed by Western blot.
Chromatin immunoprecipitation assay (ChIP)
Briefly, the A375 and SK-mel-28 cells were fixed with
1% formaldehyde, sonicated on ice to shear the DNA
into the fragments from 200 bp to 500 bp. The lysate
were subjected to immunoprecipitations with anti-p65
or non-specific rabbit IgG. The immunoprecipitated
DNA was subjected to PCR to amplify a 220 bp frag-
ment of hTERT promoter or a 510 bp fragment of iNOS
promoter. The PCR products were run electrophoretic-
ally on a 1% agarose gel and visualized by ethidium
bromide staining.
Confocal immunofluorescence assay
A375 and SK-mel-28 cells were incubated on chamber
slides in 6-well plates with indicated treatment, cells
fixed for 10 min at room temperature (RT) with 4%
paraformaldehyde, and then permeabilized with PBST
(PBS with 0.2%Triton X-100), blocked with bovine
serum albumin (BSA) 30min and incubated with
Cytochrome-c, or p65 or p50 antibodies (1:200 dilution)
for overnight at 4 °C. Following 10-min washes for three
times with PBS, cells were incubated with the fluorescein
isothiocyanate- and rhodamineconjugated secondary anti-
bodies for 30min. Subsequently, the nuclei of stained
samples were mounted with Vectashield solution contain-
ing 4′6-diamidino-2-phenylindole (DAPI). After five
additional 10-min washes, the results were visualized by
Leica DM 14000B confocal laser scanning microscope.
Xenograft tumor models of human melanoma
Male nude mice (4-5 weeks old) were obtained. All
animal maintenance and procedures were carried in
accordance with the National Institute of Health Guide
for the Care and Use of Laboratory Animals, with the
approval of the Animal Research Committee of Dalian
Medical University. A375 melanoma cells (2 × 106) were
inoculated subcutaneously into the flank of the nude
mice. Mice were randomly divided into 4 groups (5 mice
per group): DMSO, melatonin (25 mg/kg), vemurafenib
(20 mg/kg) and melatonin + vemurafenib, which were
started 5 days after injection and co-treatment every
other day for 2 weeks. The tumor volume in mm3 was
calculated as V = (width2 × length)/2 using digital
calipers and the tumor weight was recorded after the
mice were sacrificed. Partial tumor was lysed for protein
expression analysis through western blot analysis, and
partial was sliced and fixed in formalin and embedded in
paraffin for protein expression analysis through the
immunohistochemical staining.
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Briefly, Tumors were dissected and fixed in 10%
formalin overnight, embedded in paraffin, and incised to
4 um thick. Immunohistochemistry (IHC) staining was
performed using following the DAB Kit (Origene,
China). The primary antibodies iNOS, hTERT, p-p65,
Epcam, CD44, PCDNA were used with indicated
dilution ratio. Sections were stained with hematoxylin to
recognize nucleus.
Statistical analysis
Data are represented as mean ± standard deviation (SD).
Analysis of variance and Student’s t test were used to
compare the values of the test and control samples.
P < 0.05 was considered to be a statistically significant dif-
ference. SPSS17.0 software was used for statistical analysis,
and all the experiments were done three times.
Results
Melatonin potentiated vemurafenib-mediated inhibition
of cell proliferation via cell cycle arresting
To assess the effect of melatonin on vemurafenib-
mediated inhibition of cell proliferation, we tested cell
viability in a panel of human melanoma cell lines. The
expression of BRAF V600E mutant protein was firstly
determined in different cell lines (Additional file 1:
Figure S1A). Cells were treated with vemurafenib (0, 0.5,
1, 2, 4, or 8 μM) or various concentrations of melatonin
(0, 0.5, 1, 2, 4, or 8 mM) for 24 h. Vemurafenib signifi-
cantly decreased the cell viability compared with the
untreated control in melanoma cell lines with BRAF
V600E mutant, and combined treatment with melatonin
significantly enhanced the suppression of cell viability in
a dose-dependent manner compared with the treatment
with vemurafenib alone (Fig. 1a). By contrast, no im-
proved suppression was observed in A431 cells with
wild-type BRAF when they were co-treated by vemurafe-
nib and melatonin (1 mM) by comparison with the treat-
ment with vemurafenib alone (Fig. 1a). We next
determined the half-maximum inhibitory concentration
(IC50) together with cell viability assays (Fig. 1b), and
found that melanoma cells with BRAF mutant (V600E)
under co-treatment of vemurafenib and melatonin was
more sensitive to vemurafenib. We next established
A375 cell line with the relative vemurafenib resistance,
A375R (Additional file 1: Figure S1B), and similarly
found that the combined use of vemurafenib and
melatonin significantly decreased IC50 of vemurafenib
(Additional file 1: Figure S1C, D). Furthermore, the
combination of vemurafenib and melatonin also exhib-
ited lower colony formation ratio by comparison with
the cells treated with the single agent (Fig. 1c). In
addition, we assessed the effects of drug treatment on
AKT signaling, which may be involved in cellproliferation inhibition. We found the combinational
drug treatment caused a significant decrease of p-PDK1
and p-AKT and increase in levels of p-PTEN (Fig. 1D).
These findings suggested that melatonin sensitized
vemurafenib-mediated anti-proliferative function by
targeting AKT signaling.
Cell cycle is closely related with tumor intensive prolif-
eration and subdued apoptosis. To assess whether cell
cycle was implicated in the synergistic activity of vemur-
afenib and melatonin on cell viability, FACS analysis was
performed. Treatment with melatonin (1 mM) alone
increased the number of cells at G1-phase while vemur-
afenib (2.5 μM) alone significantly increased the sub-G1
cell population. Importantly, combination of melatonin
(1 mM) with vemurafenib (2.5 μM) significantly en-
hanced the induction of cell cycle arrest at G1-phase
compared with the treatment with vemurafenib alone
(Fig. 1e). Consistently, combined treatment of vemurafe-
nib (2.5 μM) and melatonin (1 mM) caused a decrease of
cyclin B, cyclin D3 and CDK2 (Fig. 1f ).
Melatonin enhanced vemurafenib-mediated inhibition of
cell migration and invasion in melanoma cells
We also evaluated the influence of the combined
treatment with melatonin and vemurafenib on the cell
migration and invasion ability in melanoma cells. The
scratch assay was employed to determine the combined
effect of vemurafenib with melatonin on cell migration
in melanoma cells. We found that the part of gap or
wounding space between cell layers was occupied almost
or completely by the migrating cells after 36 h in the
control group and the group with melatonin treatment
alone (Fig. 2a). The treatment with vemurafenib
(2.5 μM) alone inhibited cell migration. However, the
combined treatment with melatonin (1.0 mM) markedly
enhanced vemurafenib-mediated inhibition of cell mi-
gration in melanoma cells (Fig. 2a, b). These results sug-
gested that the combinational use of vemurafenib and
melatonin showed more potential effect in suppressing
cell migration in melanoma cells. Consistent with cell
migration inhibition, the combinational use of vemurafe-
nib and melatonin led to a statistically significant decrease
in melanoma cells in metastasis and invasiveness com-
pared with the single compound treatment (Fig. 2c, d). In
addition, the combination caused a decrease of
Vimentin and β-caternin and increase in levels of
E-cadherin (Fig. 2e). In agreement with this, the elevated
migration and invasion inhibition upon co-treatment with
vemurafenib and melatonin compared to vemurafenib
treatment alone was identified in A375R cells (Additional
file 1: Figure S2A, B). These findings suggested that the
combination of vemurafenib and melatonin might
suppress epithelial-mesenchymal transition (EMT) of
melanoma cells.
AB
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Fig. 1 Melatonin enhanced the inhibition of cell proliferation by vemurafenib. (a). Human melanoma cells were treated with the increasing doses
of vemurafenib (VE), melatonin (MT) alone or combined for 48 h, and the cell viability was examined by MTT assay. (b). The IC50 values of
vemurafenib (VE) for cell viability inhibition in cells treated with or without melatonin (MT) were determined. (c). Clone formation in A375 cells
and SK-mel-28 cells treated with vemurafenib (VE) (2.5 μM) and melatonin (MT) (1.0 mM) for 48 h were observed and the colony number were
quantified. (d). AKT signaling-associated protein markers: PDK1, p-PTEN, p-AKT and AKT was respectively detected by Western blot assay in
melanoma cells with indicated treatment. (e). DNA content-based cell cycle analysis was carried out in melanoma cells treated with VE or MT
alone or their combination for 48 h. The percentage of cells at each phase of cell cycle was quantified. (f). G1/S checkpoint pathway was
detected by Western blot assay in melanoma cells with indicated treatment. The data is presented as mean ± SD of three separate experiments,
*P < 0.05, **P < 0.01, significant differences compared to the control groups
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modulating cytochrome c and caspase signaling pathway
To assess whether the synergistic inhibition of vemurafe-
nib and melatonin on cell growth in melanoma cells is
associated with cell apoptosis, we confirmed the
pro-apoptotic function of such combinational use by
FACS analysis. As shown in Fig. 3a, treatment with
vemurafenib alone at the doses of 2.5 μM induced 6.5
and 3.8% apoptotic cells in A375 and SK-mel-28 cells
respectively. However, the addition of melatonin (1 mM)
greatly increased vemurafenib-induced apoptosis, result-
ing in a 13.2 and 6.4% induction of apoptosis in melan-
oma cells respectively at 24 h after treatment (Fig. 3a).
We further compared the damage extent of cells
co-treated with vemurafenib and melatonin by AO/EBstaining. The phenomenon that more EB passed through
damaged cell membrane, embedded in nucleus DNA,
and much brighter orange red fluorescence accumulated
in the nucleus was observed in the group treated with
combined compounds (Fig. 3b), indicating that more
apoptosis was induced in melanoma cells when they
were exposed to vemurafenib and melatonin simultan-
eously but not to single compound alone.
Moreover, we performed immunofluorescence (IF)
analysis to monitor the subcellular localization of
cytochrome c, which is an upstream molecule of the
caspase cascade-dependent apoptotic signaling pathway.
We found that treatment with vemurafenib (2.5 μM) or
melatonin (1 mM) alone for 24 h triggered the release of
cytochrome c from the inter-mitochondrial space into
A B
C E
D
Fig. 2 Melatonin enhanced the inhibition of cell migration and invasion by vemurafenib’ (a). Cell migration was analyzed by a scratch assay. A375
cells and SK-mel-28 cells were grown to full confluency. The cell monolayers were wounded with a sterile pipette tip, and washed with medium
to remove detached cells from the plates. Then the cells were treated with vemurafenib (VE) (2.5 μM), melatonin (MT) (1.0 mM) or combinational
treatment. After 36 h, the wound gap was observed and photographed. (b). The distance of migration cells were calculated relative to the
original gap. (c). Cell invasion was analyzed by a transwell assay, and the invaded cells were stained and observed. (d). The invasion cells number
were presented. (e). EMT markers: MMP1, Vimentin, E-cadherin and β-caternin was respectively detected by Western blot assay in melanoma cells
with indicated treatment.*P < 0.05, significant differences between the VE + MT-treated groups and the VE-treated groups
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treatment with these two drugs markedly elevated the
release of cytochrome c (Fig. 3c). Importantly, we also
observed that melatonin (1 mM) remarkably promoted
vemurafenib-induced activation of cleaved caspase-3,
cleaved caspase-9 and inactivation of Bcl-2 as well as
cleavage of PARP in melanoma cells (Fig. 3d). Collectively,
melatonin increased vemurafenib-induced pro-apoptosis
by modulating cytochrome c and caspase signaling
pathway in melanoma cells.
Melatonin enhanced vemurafenib-induced inhibition of
iNOS expression by inhibiting NF-κB signaling pathway
Inducible nitric oxide synthase (iNOS), one of
pro-inflammatory cytokines, which is also the directdownstream effectors of NF-κB, has been previously
identified as important inducers of cell proliferation,
migration, and angiogenesis in melanoma cells. In order
to identify the involvement of iNOS expression and the
further mechanistic basis in melatonin-sensitized prolif-
erative inhibition mediated by vemurafenib, we analyzed
the effect of combinational treatment on iNOS expres-
sion. We found that vemurafenib (2.5 μM) alone de-
creased the expression of iNOS. However, co-treatment
with vemurafenib (2.5 μM) and melatonin (1 mM)
almost diminished the expression of iNOS compared
with vemurafenib treatment itself (Fig. 4a). In addition,
treatment with iNOS si-RNA alone showed inhibitory
effect on cell viability, however, the combined treatment
with melatonin, vemurafenib and si-iNOS markedly
A B
C D
Fig. 3 Melatonin increased apoptosis induced by vemurafenib via the cytochrome c/caspase signaling pathway. Human melanoma cells were
treated with vemurafenib (VE) (2.5 μM) and melatonin (MT) (1.0 mM) for 24 h. (a). The apoptosis was then determined by a FACS analysis.
(b). Acridine orange/ethidium bromide fluorescence staining was performed in melanoma cells. (c). The release of cytochrome c (cyto-c) was
monitored by immunofluorescence imaging analysis from the inter-mitochondrial space into the cytosol. (d). The levels of the Bcl-2, cleaved,
caspase-3, 9 and PARP proteins were analyzed by Western blotting. The apoptosis are represented by relative percentages of apoptotic cells
versus that in DMSO-treated cells
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suggested that the elevated proliferative inhibition by
co-treatment with melatonin and vemurafenib might
partially be realized through inhibiting the activation of
iNOS signaling.
It has also been shown that NF-κB activation protects
cells from BRAF inhibition-induced cell death. We next
determined the level of p50/p65 in the cell lysate, and
found that vemurafenib (2.5 μM) or melatonin (1 mM)
treatment alone reduced the expression of p50/p65 in
the nuclei of melanoma cells (Fig. 4c), and the treatment
with melatonin and vemurafenib markedly inhibited
translocation of the NF-κB p65/p50 proteins from cell
cytoplasm to nucleus by comparison with the control
treatment group (Fig. 4c, d). Furthermore, we deter-
mined the effect of the combinational treatment on the
binding of p65 at iNOS promoter region. Pull down andChIP assay indicated that the binding of p65 to the
iNOS promoter was almost diminished after
co-treatment with melatonin and vemurafenib (2.5 μM)
compared to the single compound treatment alone
(Fig. 4e, f ). These results indicate that the inhibition
of iNOS expression in melanoma cells by combin-
ational use of melatonin and vemurafenib might be
mediated by inhibiting the translocation of NF-κB
p50/p65 from cytoplasm to cell nuclei and further
inhibiting their binding at iNOS promoter.
Moreover, to better understand the involvement of
NF-κB signaling pathway in the iNOS expression inhib-
ition mediated by the co-treatment of melatonin and
vemurafenib in melanoma cells, we then investigated the
upstream signaling molecules of NF-κB pathway. As
shown in Fig. 4g, the combinational treatment not only
significantly suppressed the phosphorylation of IKKβ in
A B C
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Fig. 4 Melatonin enhanced the vemurafenib-induced inhibition of INOS expression by inhibiting NF-κB signaling pathway. (a). The expression
level of iNOS and p-P65 protein were analyzed by Western blot in human melanoma cells treated with the indicated doses of vemurafenib (VE)
(2.5 μM) and melatonin (MT) (1.0 mM) for 48 h. (b). Cell viability was analyzed by MTT assay in melanoma cells treated with vemurafenib (2.5 μM)
combined with or without MT (1.0 mM) for 24 h after pretreatment with the iNOS targeting siRNA for 48 h. (c). The expression of p50/p65 was
determined from nucleus extracts prepared from melanoma cells by Western blotting. (d). The subcellular localization of p50 and p65 and their
co-localization in human melanoma cells treated with 2.5 μM vemurafenib (VE) and 1.0 mM melatonin (MT) for 48 h were examined by confocal
microscopy. Cells with typical morphology were presented from more than 100 cells at each experiment. (e). The streptavidin-biotin pulldown
assay was performed to analyze the binding of P65 protein to iNOS promoter in melanoma cells with the indicated treatment. (f). Binding of p65
to the iNOS promoter in chromatin structure by ChIP assay. IgG, a negative control for ChIP in melanoma cells with the indicated treatment.
(g). Human melanoma cells were treated with 2.5 μM vemurafenib (VE) and 1.0 mM melatonin (MT). At 48 h after treatment, the IKKβ, p-IKKβ, IκBα
and p-IκBα proteins were analyzed by Western blotting. (h). Vemurafenib (VE) combined with or without 1.0 mM melatonin (MT) followed by
NF-κB inhibitor treatment and then iNOS expression and cell viability was respectively analyzed Western blot. (i). MTT assay in melanoma cells
treated with NF-κB Activation Inhibitor followed by the treatment of vemurafenib (VE) combined with or without 1.0 mM melatonin (MT). Each
data point was calculated from three triplicate groups and the data is presented as the mean ± SD. *P < 0.05, significant difference between
treatment group and control group
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but also decreased the expression level of phosphory-
lated IκBα. Next, we investigated the effect of NF-κB
inhibitor on iNOS expression and cell viability upon
co-treatment with melatonin and vemurafenib. The
results indicated compared to single melatonin and
vemurafenib co-treatment, NF-κB signaling inhibition
caused more iNOS expression suppression and cell via-
bility inhibition (Fig. 4h, i). Collectively, NF-κB signaling
pathway was a potential target of co-treatment withmelatonin and vemurafenib in melanoma cells to finally
suppress iNOS expression.
Melatonin enhanced vemurafenib-induced inhibition of
cancer stem cell traits by down-regulating hTERT in
melanoma cells
Next, to assess the effect of the combinational treatment
on the stemness of melanoma cells, tumor-sphere model
was performed and we found melatonin significantly in-
creased the inhibition of vemurafenib on the tumorsphere
Hao et al. Journal of Experimental & Clinical Cancer Research           (2019) 38:48 Page 10 of 15size in both A375 and SK-mel-28 cells (Fig. 5a). Consist-
ently, cell-surface phenotype analysis indicated that the
combinational treatment decreased CD44 expression on
the surface of melanoma cells (Fig. 5b). To further investi-
gate the mechanism of the combinational effect related to
melanoma stem cell traits, we determined the expression
levels of cancer stem cell (CSC)-related markers, including
Epcam, CD44, OCT4 and c-kit. The co-treatment of
melatonin and vemurafenib remarkably inhibited their ex-
pression (Fig. 5c).
Given the critical role of MAPK pathway in BRAF-
targeting therapy resistance and the existence of
Erk-MSK1-P65 signaling as the alternative pathway ofA
F
B
E
Fig. 5 Combination of vemurafenib and melatonin inhibited cancer stem c
melanoma cells were exposed to vemurafenib (VE) (2.5 μM) with or withou
tumor sphere formation of melanoma cells with indicated treatment. (b). C
FACS. (c). The expression of CSC-related markers Epcam, CD44, c-kit and Oc
the indicated treatment. (d). The expression of hTERT-p-MSK1-p65 pathway
the indicated treatment. (e). The representative images of tumor sphere fo
combined with MT (1.0 mM) for 24 h after pretreatment with the hTERT tar
hTERT promoter driven-luciferase and vemurafenib (VE) (2.5 μM) with or wi
relative luciferase intensity per mg protein was calculated in the treated ce
analyze the binding of P65 protein to hTERT promoter in melanoma cells w
promoter in chromatin structure by ChIP assay. IgG, a negative control for
presented as the mean ± SD of three separate experiments. *P < 0.05, signifMAPK pathways, we then evaluated the effect of the
co-treatment on this pathway and found vemurafenib
combined with melatonin remarkably down-regulated
their phosphorylated level by comparison to vemurafe-
nib or melatonin treatment alone (Fig. 5d). Moreover,
the expression of hTERT, which is mutually stabilized by
p65 acting as a molecular buttress in catalytically active
conformations, and plays an important role in the main-
tenance of stem cell traits, was also significantly inhib-
ited by the combinational treatment (Fig. 5d). Treatment
with hTERT sh-RNA alone similarly showed inhibitory
effect on the tumorsphere number and size, however,
the combined treatment with melatonin, vemurafenibC
D
G
H
ell traits by down-regulating hTERT in melanoma cells. Human
t melatonin (MT) (1.0 mM) for 48 h. (a). The representative images of
D44 expression on the surface of melanoma cells was analyzed by
t4 were determined by western blot in A375 and SK-mel-28 cells with
were determined by western blot in A375 and SK-mel-28 cells with
rmation of melanoma cells treated with DMSO or vemurafenib (2.5 μM)
geting shRNA. (f). Melanoma cells were co-treated with the plasmids of
thout melatonin (MT) for 48 h followed by a dual-luciferase assay. The
lls. (g). The streptavidin-biotin pulldown assay was performed to
ith the indicated treatment. (h). Binding of p65 to the hTERT
ChIP in melanoma cells with the indicated treatment. The data are
icant differences between treatment groups and DMSO control groups
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(Fig. 5e), further confirming the involvement of hTERT
in the stemness weakening mediated by the combined
use of melatonin and vemurafenib.
We then assessed the effect of the combinational
treatment on hTERT promoter activity in melanoma cells,
and found that co-treatment of melatonin and vemurafe-
nib markedly attenuated the expression of hTERT
promoter-driven luciferase as compared with control
group or single drug treatment group (Fig. 5f). To further
provide mechanistic insights into hTERT expression
regulated by the combinational treatment of melatonin
and vemurafenib, we explored the possibility of p65 par-
ticipating in the hTERT expression in melanoma cells
treated by melatonin and vemurafenib. Pull down (Fig. 5g)
and ChIP assay (Fig. 5h) indicated that the binding of p65
to the hTERT promoter was almost diminished after
co-treatment with melatonin and vemurafenib compared
to the single compound treatment alone. These results
indicate that the inhibition of hTERT expression in
melanoma cells by combinational use of melatonin and
vemurafenib might be mediated by inhibiting the binding
of p65 at hTERT promoter.
Inhibition of tumor growth and CSC properties by
melatonin and vemurafenib in mouse model with
melanoma xenografts
We also validated the combinational treatment-mediated
regulation of tumor growth in a mouse model with
melanoma xenografts. A375 cells were injected into
nude mice (flank), and we found the mice with subcuta-
neous xenografts of melanoma cells displayed remark-
able tumor growth delay when they were co-treated with
melatonin and vemurafenib (Fig. 6a, b, c). Limiting dilu-
tion assays showed no tumor was formed in combined
treatment group when cell number injected was 1 × 104
(Fig. 6d). Further, Western blot and immunohisto-
chemistry analyses showed that combination of
melatonin and vemurafenib not only remarkably sup-
pressed the expression of hTERT, iNOS, p65, CD44
and Epcam, but also decreased the level of PCNA in
xenografts, compared with the single drug treatment
or control group (Fig. 6e, f ). These results demonstrated
again the improved antitumor effect of vemurafenib upon
co-use with melatonin in melanoma treatment, and also
confirmed the involvement of p65/iNOS/hTERT signaling
in the co-treatment-mediated regulation of melanoma
growth and CSC expansion.
Discussion
Synergistic antitumor effect of melatonin and vemurafenib
Chapman PB et al. [36] reported the response initially to
vemurafenib treatment by approximately 80% of patients
with mutant BRAF melanomas, but acquired drugresistance develops in the majority of patients commonly
within 1 year. In this study, we demonstrated that
melatonin sensitized vemurafenib-mediated antitumor
effect in melanoma cells, which was represented by the
improved cell viability suppression, clonogenicity, migra-
tion and invasion inhibition, apoptosis induction and
stemness attenuation. The IC50 value of vemurafenib
was dramatically decreased under co-treatment with
melatonin in comparison with vemurafenib treatment
alone. The increased G1 phase among melanoma cells
demonstrated cell cycle arrest might contribute to the en-
hanced proliferation inhibition caused by co-treatment
with vemurafenib and melatonin. In addition, we also
demonstrated the up-regulated expression inhibition of
iNOS and hTERT upon co-treatment of melatonin and
vemurafenib in melanoma cells, clarifying the possible
molecular mechanisms of such combinational treatment
in enhancing anti-cancer effects.
Synergistic inhibition of iNOS signaling by melatonin and
vemurafenib
Inducible NO synthases (iNOS), combined with its prod-
uct NO, has shown high expression level in melanoma,
and has been reported to be a strong predictor about
disease-specific and overall survival (OS) in stage III
melanoma patients [37]. The iNOS signaling was also
identified in the regulation of proliferation, migration in-
vasion and apoptosis in many kinds of cancer cells.
Therefore, the effective therapeutic strategy targeting
iNOS has been developed and is expected to provide
therapeutic implications in cancer treatment. Our study
found the enhanced inhibition of iNOS expression in
melanoma cells after co-treatment with vemurafenib
and melatonin in comparison with single agent
treatment. Moreover, iNOS knockdown caused more
significant proliferative inhibition in melanoma cells
mediated by the two compounds co-treatment,
suggesting that inhibition of iNOS signaling at least
partially contributed to the sensitization potential of
melatonin in vemurafenib-mediated cell proliferation
inhibition in melanoma cells.
Synergistic inhibition of NF-κB signaling by melatonin
and vemurafenib
It has been reported that NF-κB activation protects cells
from BRAF inhibition-induced cell death. Similarly, the
reactivation of the PI3K/Akt-CREB-AEBP1-NF-κB path-
way showed to contribute to BRAF inhibitor-resistant
phenotype in melanoma treatment [38, 39]. Given that
iNOS expression is classically regulated by NF-κB
signaling, we therefore initially focused on its participa-
tion in venurafenib-mediated regulation of iNOS expres-
sion. Our study identified co-treatment with melatonin
and venurafenib inhibited the NF-κB signaling by
A B C
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Fig. 6 Combination of vemurafenib and melatonin inhibited tumor growth and CSCs properties in mice. (a). The morphology of tumor
xenografts of each nude mice after anatomy at 15 days of treatment. (b). Tumor volume of each group of nude mice was measured and
calculated as V = (width2 × length)/2. (c). Tumor weight of each group of nude mice was measured, *P < 0.05. (D). Limiting dilution assays was
performed and the finally formed tumors were calculated. (e-f). The expression levels o of iNOS, hTERT, p65, CD44, Epcam, PCNA expression from
tumor exnografts in each group of nude mice by western blot (e) and immunohistochemistry assay (f). The data in panels are presented as
the mean ± SD of three tests. P < 0.05, significant differences between treatment groups and DMSO control groups n = 5 mice/group.
Magnification, 100 ×
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vemurafenib combined with melatonin dephosphory-
lated the NF-κB subunit p65, decreased its translocation
from cytoplasm into nucleus, abrogated the binding
of the NF-κB complex to the iNOS promoter and fi-
nally led to its expression suppression. Collectively,
our results clearly show NF-κB signaling behaves as a
dependent middle bridge in the increased iNOS ex-
pression regulation mediated by the combinational
use of melatonin and vemurafenib in melanoma
treatment.
Synergistic inhibition of hTERT signaling by melatonin
and vemurafenib
Accumulating evidence demonstrated the significant role of
cancer stem cells in cancer development [40, 41]. hTERT
was found to be involved in the maintenance of stemness in
cancer cells [42, 43]. The relationship between high expres-
sion of hTERTand inferior outcome in patients with melan-
oma was reported recently [44]. Combined with the fact
that melatonin plays its antitumor effect by affecting hTERT
expression and telomerase activity [45, 46]. Hence, wededuce the improved antitumor effects displayed by the
combinational treatment of melatonin and vemurafenib
might be partially realized by the enhanced stemness abro-
gation through targeting at hTERT expression. Our study
showed that the combination of melatonin and vemurafenib
decreased the level of stemness markers, including CD44,
c-kit and OCT4, and attenuated the expression of hTERT
by impairing induction of hTERT promoter activity medi-
ated by p65. Notably, hTERT silencing led to more signifi-
cant stemness arrest in melanoma cells mediated by
co-treatment with melatonin and vemurafenib, implying the
potentiating effect of melatonin on vemurafenib-induced
stemness inhibition through the p65/hTERT signaling path-
ways, and such signaling inhibition may be a striking target
for potential therapeutics in melanoma.
Given that iNOS was similarly reported to contribute to
the promotion of cancer stem cell phenotype [47, 48], and
the combinational treatment of melatonin and vemurafenib
induced more expression inhibition of iNOS compared to
single drug treatment, it is reasonable that besides hTERT,
iNOS might also be involved in the abolished stemness
maintenance caused by the combined drug application. In
Fig. 7 The schematic diagram of the molecular mechanisms by
which melatonin synergizes vemurafenib in melanoma treatment.
The symbol (⊦) indicates negative regulation. The arrow (→)
indicates direct or indirect positive regulation
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mediates the improved proliferation suppression caused by
the combined drug treatment. All these possibilities deserve
better explorations in our further study.
Conclusion
In summary, our findings demonstrated that melatonin
potentiated the vemurafenib-mediated antitumor effect in
melanoma. The combination led to melanoma cell growth
inhibition in vitro and in vivo, as evidenced by decreased
proliferative and invasive capacity, and enhanced cell cycle
arrest and apoptosis induction. Moreover, we provided
mechanistic insight into the combination, and found that
melatonin synergizes the antitumor effect of vemurafenib
by inhibiting the iNOS/hTERT signaling and cancer-stem
cell traits in human melanoma (Fig. 7). Our findings
therefore demonstrated the potential of melatonin, not
only in antagonizing the toxicity of vemurafenib but also
in augmenting its sensitivities in melanoma treatment.
Therefore, the combinational use of a natural endogenous
hormone (melatonin) and a small molecule inhibitor
(vemurafenib) targeting BRAF should be considered as a
promising therapeutic strategy to break drug resistance in
melanoma treatment.Additional file
Additional file 1: Figure S1. Melatonin enhanced the inhibition of cell
proliferation by vemurafenib. (A). BRAF V600E, p-ERK and ERK was
respectively detected by Western blot assay in melanoma cells (A375,
SK-mel-28, G361 and A431). (B). ABCG2 was respectively detected by
Western blot assay in A375 and A375R cells. (C). Human melanoma cells
(A375R) were treated with the increasing doses of vemurafenib (VE),
melatonin (MT) alone or their combination for 48 h, and the cell viability
was examined by MTT assay. (D). The IC50 values of vemurafenib (VE) for
cell viability inhibition in A375R cells treated with or without melatonin
(MT) were determined. Figure S2. Melatonin enhanced the inhibition of
cell migration and invasion by vemurafenib (A). Cell migration was
analyzed by a scratch assay. A375R cells were treated with vemurafenib
(VE) (4 μM), melatonin (MT) (1.0 mM) or their combination. After 36 h, the
wound gap was observed and photographed, and the distance of
migration cells were calculated relative to the original gap. (B). Cell
invasion was analyzed by a transwell assay in A375R cells with different
treatment. The invaded cells were stained and observed, and the number
of the invasion cells was presented. The data is presented as mean ± SD
of three separate experiments, *P < 0.05, **P < 0.01, significant differences
compared to the control groups. (PDF 4326 kb)
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